Braveheart Bio's IPO pricing at $18 per share for an upsized 21.25 million shares, generating $382.5 million in gross proceeds, sets the baseline fully diluted valuation near $1.13 billion at the original midpoint, with shares debuting on Nasdaq under BRVE on August 6 amid a broader biotech rebound. Strong institutional demand drove the premium pricing above the $15–17 range and fueled an initial trading surge exceeding 60 percent, lifting implied market capitalization toward or beyond $1.6 billion and creating tight competition between the top two outcome buckets. Clinical-stage focus on next-generation cardiac myosin inhibitors for hypertrophic cardiomyopathy, with Phase 3 trials slated for late 2026, underpins investor appetite, while comparable recent cardiovascular biotech debuts and favorable sector sentiment add support for elevated closing levels versus lower ranges.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于16亿美元以上 27%
14.5亿美元-16亿美元 23%
10亿美元-11.5亿美元 <1%
11.5亿美元-13亿美元 <1%
$3,561 交易量
$3,561 交易量
2026-08-06
低于10亿美元
<1%
10亿美元-11.5亿美元
1%
11.5亿美元-13亿美元
1%
13亿美元-14.5亿美元
<1%
14.5亿美元-16亿美元
23%
16亿美元以上
27%
16亿美元以上 27%
14.5亿美元-16亿美元 23%
10亿美元-11.5亿美元 <1%
11.5亿美元-13亿美元 <1%
$3,561 交易量
$3,561 交易量
2026-08-06
低于10亿美元
$260 交易量
<1%
10亿美元-11.5亿美元
$486 交易量
1%
11.5亿美元-13亿美元
$539 交易量
1%
13亿美元-14.5亿美元
$981 交易量
<1%
14.5亿美元-16亿美元
$457 交易量
23%
16亿美元以上
$373 交易量
27%
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Braveheart Bio's IPO pricing at $18 per share for an upsized 21.25 million shares, generating $382.5 million in gross proceeds, sets the baseline fully diluted valuation near $1.13 billion at the original midpoint, with shares debuting on Nasdaq under BRVE on August 6 amid a broader biotech rebound. Strong institutional demand drove the premium pricing above the $15–17 range and fueled an initial trading surge exceeding 60 percent, lifting implied market capitalization toward or beyond $1.6 billion and creating tight competition between the top two outcome buckets. Clinical-stage focus on next-generation cardiac myosin inhibitors for hypertrophic cardiomyopathy, with Phase 3 trials slated for late 2026, underpins investor appetite, while comparable recent cardiovascular biotech debuts and favorable sector sentiment add support for elevated closing levels versus lower ranges.
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市场开放时间： Aug 5, 2026, 5:48 AM ET
交易量
$3,561结束日期
2026-08-06市场开放时间
Aug 5, 2026, 5:48 AM ETResolver
0x69c47De9D...This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Braveheart Bio's IPO pricing at $18 per share for an upsized 21.25 million shares, generating $382.5 million in gross proceeds, sets the baseline fully diluted valuation near $1.13 billion at the original midpoint, with shares debuting on Nasdaq under BRVE on August 6 amid a broader biotech rebound. Strong institutional demand drove the premium pricing above the $15–17 range and fueled an initial trading surge exceeding 60 percent, lifting implied market capitalization toward or beyond $1.6 billion and creating tight competition between the top two outcome buckets. Clinical-stage focus on next-generation cardiac myosin inhibitors for hypertrophic cardiomyopathy, with Phase 3 trials slated for late 2026, underpins investor appetite, while comparable recent cardiovascular biotech debuts and favorable sector sentiment add support for elevated closing levels versus lower ranges.
This market will resolve based on Braveheart Bio's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 6 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$3,561结束日期
2026-08-06市场开放时间
Aug 5, 2026, 5:48 AM ETResolver
0x69c47De9D...Braveheart Bio's IPO pricing at $18 per share for an upsized 21.25 million shares, generating $382.5 million in gross proceeds, sets the baseline fully diluted valuation near $1.13 billion at the original midpoint, with shares debuting on Nasdaq under BRVE on August 6 amid a broader biotech rebound. Strong institutional demand drove the premium pricing above the $15–17 range and fueled an initial trading surge exceeding 60 percent, lifting implied market capitalization toward or beyond $1.6 billion and creating tight competition between the top two outcome buckets. Clinical-stage focus on next-generation cardiac myosin inhibitors for hypertrophic cardiomyopathy, with Phase 3 trials slated for late 2026, underpins investor appetite, while comparable recent cardiovascular biotech debuts and favorable sector sentiment add support for elevated closing levels versus lower ranges.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题